VolitionRx insider adds 48,076 warrants, $0.60 exercise price

Rhea-AI Filing Summary

VolitionRx (VNRX) director reported buying 48,076 shares of common stock on October 14, 2025 in an underwritten public offering. The stock was acquired at $0.51 per share, and the purchase included warrants for 48,076 shares exercisable at $0.60 until October 14, 2030. The total unit price was $0.52, with $0.01 allocated to the warrant.

Following the transaction, the reporting person beneficially owned 1,535,458 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

STILL TIMOTHY I

(Last) (First) (Middle)

1489 WEST WARM SPRINGS ROAD,

SUITE 110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/14/2025		P		48,076(1)	A	$0.51	1,535,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$0.6	10/14/2025		P		48,076(1)		10/14/2025	10/14/2030	Common Stock	48,076	$0.01	48,076	D

Explanation of Responses:

1. The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant.

Remarks:

	/s/ Timothy I. Still	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VolitionRx (VNRX) insider buy?

A director bought 48,076 shares of common stock and received 48,076 accompanying warrants.

At what price were VNRX shares acquired?

The shares were acquired at $0.51 per share; the unit price was $0.52 with $0.01 allocated to the warrant.

What are the terms of the VNRX warrants?

The warrants are exercisable at $0.60 per share from October 14, 2025 and expire on October 14, 2030.

How many VNRX shares does the insider own after the trade?

The reporting person beneficially owned 1,535,458 shares directly after the transaction.

What was the context of the VNRX insider purchase?

The shares and warrants were purchased from the underwriter in an underwritten public offering that closed on October 14, 2025.

How many warrants did the VNRX insider receive?

The insider received 48,076 warrants, each for one share of common stock.